This $256,000 National Science Foundation Project Grant under the Engineering (47.041) program will support the development of a permanent ceramic antimicrobial coating technology by Nanoionix, LLC. The goal is to synthesize and deposit a pure ceramic coating on relevant substrates that exceeds EPA requirements for generating reactive oxygen species to inactivate viruses and bacteria. Nanoionix will conduct spectroscopic assessments to rapidly evaluate the types and numbers of reactive oxygen...
This federal Project Grant award from the Agency for Healthcare Research and Quality (AHRQ), under the Research on Healthcare Costs, Quality and Outcomes (CFDA 93.226) program, aims to determine if contact precautions should be used for patients with Clostridioides difficile (C. difficile) colonization. The key products or services to be delivered include: Assessing the frequency, location, and amount of environmental C. difficile contamination among 300 patients with C. difficile colonization...
Acatechol, Inc. was awarded a $274,982 National Science Foundation (NSF) Small Business Innovation Research (SBIR) Phase I grant to develop an innovative anti-infective coating for Foley catheters. The project aims to create a hybrid coating that combines biofilm-repellent and antimicrobial properties to provide prolonged resistance against pathogen colonization and catheter-associated urinary tract infections (CAUTIs). This work is being conducted under the NSF Technology, Innovation, and...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $840,462 to Mississippi State University to conduct research on the structure, orientation, and competitive interactions of Staphylococcus epidermidis biofilm proteins on medical implant surfaces. The key objectives are to: 1) establish the rules governing how S. epidermidis proteins bind to and interact with...
This Project Grant, awarded by the National Heart Lung and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), aims to develop a unique antimicrobial vascular catheter to prevent catheter-related bloodstream infections (CRBSI). The $272,702 award, effective September 1, 2023, with a completion date of February 29, 2024, will support research and development efforts to create an intravascular catheter with inherent long-lasting antiseptic properties. The...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), will provide $197,748 to conduct research on healthcare-associated infections (HAIs) and antimicrobial resistance (AMR) in neonatal intensive care units (NICUs). The key objectives of this research project are to: 1) Identify nosocomial transmission of viral and bacterial pathogens in the NICU through metagenomic...
The National Science Foundation Division of Industrial Innovation awarded Quick-Med Technologies, Inc. a $255,999 Project Grant under the Engineering federal grant program (CFDA 47.041) to develop Regenerable Antimicrobial Paints Based on Hydrogen Peroxide. This award, issued on April 1, 2021 for completion by September 30, 2021, will support Quick-Med Technologies' efforts to improve the quality of life and economic strength of the nation by fostering innovation in engineering research....
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $300,000 to Ionic Pharmaceuticals, LLC to develop a novel quorum sensing inhibitor-based wound dressing to treat second-degree burn wound infections caused by methicillin-resistant Staphylococcus aureus (MRSA). The key objectives are to: 1) optimize the formulation of the W-hydroxyemodin-loaded hydrogel-based wound...
This $400,000 Project Grant award from the Center for Quality Improvement and Patient Safety (Agency for Healthcare Research and Quality, CFDA 93.226 - Research on Healthcare Costs, Quality and Outcomes) will support the dissemination of a facilitation strategy to reduce unnecessary post-operative antibiotic use in children's hospitals. The Research Institute at Nationwide Children's Hospital (RINCH) will adapt their existing evidence-based facilitation workshop and deliver it virtually to...
The National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), awarded a $595,834 Cooperative Agreement to Trellis Bioscience, Inc. to conduct a Phase 1 safety trial for the company's TRL1068 monoclonal antibody therapy. The TRL1068 antibody is designed to disrupt bacterial biofilms, which can enhance the effectiveness of conventional antibiotics and address antibiotic resistance. The proposed research aims to evaluate...